PSVT is a disease with a significant unmet need

PSVT can significantly affect the quality of life of patients due to episodes of tachycardia that can come at any time without warning. Currently, there are no self-administered drug treatment options approved by the FDA to stop PSVT episodes when they start.

Find out more about PSVT

Milestone is committed to improving the lives of PSVT patients

For more than a decade, Milestone has been working to develop new therapies intended to stop PSVT episodes when they start.

Learn more about Milestone’s R&D program.

About Milestone

Milestone Pharmaceuticals Inc. is a private venture capital-funded cardiovascular drug development company developing novel small molecule therapeutics for transient cardiovascular conditions. The company’s lead product, etripamil (MSP-2017), is entering Phase 3 development. Etripamil is a potent and short-acting nasally-delivered calcium channel antagonist in development for the episodic treatment of paroxysmal supraventricular tachycardia (PSVT).

Learn More

Featured News

Milestone Pharmaceuticals to Present Etripamil Phase 2 Data at the Heart Rhythm Society’s 38th Annual Scientific Sessions Data from NODE-1 Trial to be Presented as Part of Late Breaking Oral Session May 11th

Read More | All News Stories